Annika Smith

Annika Smith

Auto-generated profile, based on publicly available information

Annika Smith

Faculty of Medicine and Health, University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Melanoma Research
Verified
Journal Article
Closed access
SMScott W. Menzies
Scott W. Menzies
SLSakitha Liyanarachchi
Sakitha Liyanarachchi
ECElliot Coates
Elliot Coates
ASAnnika Smith
Annika Smith
CCClaire Cooke-Yarborough
Claire Cooke-Yarborough
PGPascale Guitera
Pascale Guitera
Little is known about the risk of progression of lentigo maligna to lentigo maligna melanoma. We determine the annual risk of progression of lentigo maligna to lentigo maligna melanoma by analysing a prospective population-based survey of recently diagnosed anterior (visible in a mirror) head and neck lentigo malignas and lentigo maligna melanomas. Six hundred eighty-two consecutive patients aged 18–80 years with non-recurrent lentigo maligna or lentigo maligna melanoma, diagnosed between 1 July 2015 and 20 April 2016, were identified from pathology notifications to the New South Wales Cancer Registry (Australia) and sent survey questionnaires soon after diagnosis (median 4.6 months interquartile range: 3.8–5.7). Details of the time the lesion was present and when changes to it were noticed before diagnostic biopsy were ascertained by surveying the patients, of whom 53.5% agreed to participate. There was little difference between the proportions of lentigo maligna melanoma and lentigo maligna in the consenting and non-consenting patients (P = 0.56). Two hundred twenty-eight lentigo maligna (median age 67 years, range: 38–80) and 33 lentigo maligna melanoma (70 years, 43–80) were surveyed. There was no difference between the time lentigo maligna melanoma was present on the skin (median 18 months, range: 0–690) and the time lentigo maligna was (18 months, 0–665) (P = 0.972). The estimated risk of progression of lentigo maligna to lentigo maligna melanoma was 3.5% per year (95% confidence interval: 2.5–5.0). This equates to an average time for lentigo maligna to progress to lentigo maligna melanoma of 28.3 years (95% confidence interval: 20.0–40.5) in this population. Although our data suggests that the annual progression rate of lentigo maligna is more than 25 times greater than previously suggested, the rate is still low.

1 November 2011 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
ASA. Smith
A. Smith
Justin DenholmJustin Denholm
Justin Denholm
JSJake Shortt
Jake Shortt
DSD. Spelman
D. Spelman

22 January 2025 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
ASAnnika Smith
Annika Smith
AKAidin Karahasan
Aidin Karahasan
DYDeborah Yi
Deborah Yi
SYSanjay Yapabandara
Sanjay Yapabandara
JEJames Elhindi
James Elhindi
SZSarah Zaman
Sarah Zaman
Introduction Psoriasis is a systemic inflammatory disease with increased cardiometabolic risk including dyslipidaemia and diabetes. Biologic therapy effectively treats the cutaneous inflammatory burden of psoriasis and evolving evidence suggests potential to reduce systemic inflammatory sequalae that can elevate cardiovascular risk. This study aimed to assess the change in cardiometabolic risk markers in a cohort of patients with psoriasis treated with 1 year of continuous biologic treatment. Methods A retrospective review was conducted of patients receiving biologic therapy for chronic plaque psoriasis in a single dermatology centre at a major tertiary hospital in Sydney, Australia. The effect of biologic therapy on psoriasis was assessed using the psoriasis area severity index (PASI). Cardiometabolic risk markers assessed included lipid profile (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol and triglycerides [TG]) and haemoglobin A1c (HbA1c). Measurements at baseline and 1 year were compared using paired t tests for analysis of the parameters which approximated normal distribution (TC, LDL, HDL) and Wilcoxon signed-rank test for analysis of those which did not (TG, HbA1c, PASI). Two-tailed P values < 0.05 were considered significant. Results A total of 200 patients were reviewed, of which 39 had complete data sets. The participants’ ages ranged from 21 to 85 years (mean 51, SD 16.9). Of the 39 participants, 31 (79.5%) were male, 8 (20.5%) were female; 26 (67%) were biologic experienced (BE) and 13 (33%) were biologic naïve (BN). The mean PASI at baseline (for BN + BE) was 13.4 (SD 9.8). The biologic agents used, according to frequency, included risankizumab, with 14 participants (35.9%), secukinumab by 7 (17.9%), ustekinumab by 6 (15.4%), ixekizumab by 6 (15.4%), guselkumab by 3 (7.7%), infliximab by 2 (5.1%), and adalimumab by 1 (2.6%). After 12 months, significant skin improvement was seen [PASI reduced from 13.43 (SD 9.8) to 1.1 (SD 2.1), p < 0.001]. There was no significant change in lipid profile, including TC (mean difference − 0.1 mmol/L, p = 0.532), LDL-C (mean difference = − 0.1 mmol/L, p = 0.476), HDL (mean difference = − 0.1 mmol/L, p = 0.125), triglycerides (mean difference = 0.0 mmol/l, p = 0.748) or HbA1c (mean difference 0.38%, p = 0.468). Conclusion Markers of cardiometabolic risk (lipid profile and HbA1c) did not significantly improve after 1 year of biologic therapy despite significant reduction in psoriasis skin severity. Further research in larger cohorts is needed to elucidate the benefits, if any, of biologic therapy on cardiometabolic parameters in individuals with psoriasis, in order to optimise care for this vulnerable cohort.

27 October 2025 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
VMVaritsara Mangkorntongsakul
Varitsara Mangkorntongsakul
JJJ. S. Joseph
J. S. Joseph
JPJames P. Pham
James P. Pham
SSSaxon D. Smith
Saxon D. Smith
CCClara K. Chow
Clara K. Chow
ASAnnika D. Smith
Annika D. Smith
Introduction Cardiovascular disease is a leading co-morbidity in psoriasis patients. The cutaneous benefits of biologic therapies for severe plaque psoriasis are well-established, but the impact of biologics on major adverse cardiovascular events (MACE) in psoriatic patients requires further elucidation. This study aimed to investigate the impact of biologic therapies on the risk of MACE in patients with chronic plaque psoriasis. Methods We conducted a systematic review and meta-analysis on 10 May 2022, using Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR) and EMBASE databases for relevant studies. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) methodology was applied, and all studies were critically appraised. All studies selected for inclusion were randomised control trials (RCTs) that contained data on MACE and compared licensed biologic therapies with placebo or other biologics in adults with moderate-severe plaque psoriasis. Results The search of the databases revealed 36 papers (reporting on 43 RCTs) which met the inclusion criteria. No statistically significant difference in the risk for MACE between biologic therapies and placebo was found [Peto odds ratio (POR) 1.26, 95% confidence interval (CI) 0.53–3.01, P = 0.59]. A comparison of specific types of biologics also revealed no significant effect in adult patients with moderate-to-severe plaque psoriasis: tumour necrosis factor (TNF)-alpha inhibitors (adalimumab, infliximab, etanercept) (POR 1.13, 95% CI 0.29–4.32 P = 0.86), interleukin (IL)-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) (POR 0.60, 95% CI 0.16–2.25, P = 0.45); IL 12/23 inhibitors (usetekinumab) (POR 3.80, 95% CI 0.37–39.44, P = 0.26) and IL-23 (guselkumab, risankizumab, tildrakizumab) (POR 1.75, 95% CI 0.25–12.43 P = 0.58). Conclusions Anti-psoriatic biologics were not associated with an increased risk of MACE in psoriasis patients. Given that most included RCTs were of relatively short duration, longer-term studies and post-marketing surveillance are needed to clarify the cardiovascular safety profile of biologic therapies. Further large-scale studies with extended follow-up are warranted. Study registration This study was prospectively registered on PROSPERO (identification number CRD42022325792).

5 May 2022 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
JPJames Pham
James Pham
PSPhoebe Star
Phoebe Star
LALuke Ardolino
Luke Ardolino
ASAnnika Smith
Annika Smith
AJAnthony Joshua
Anthony Joshua

21 September 2022 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
JPJames Pham
James Pham
NANicholas Allen
Nicholas Allen
ASAnnika Smith
Annika Smith